Literature DB >> 31904570

Combination of intraoperative radiofrequency ablation and surgical resection for treatment of cholangiocarcinoma: feasibility and long-term survival.

Sang Min Lee1, Heung Kyu Ko2, Ji Hoon Shin2, Jin-Hyoung Kim2, Hee Ho Chu2.   

Abstract

PURPOSE Most patients with intrahepatic cholangiocarcinoma (ICC) are not eligible for surgical resection due to advanced stage. We aimed to evaluate the feasibility, local tumor control, and long-term survival of intraoperative radiofrequency ablation (IORFA) with surgical resection to treat unresectable intrahepatic cholangiocarcinoma (ICC). METHODS From 2009 to 2016, 20 consecutive patients (12 primary ICC, 8 recurrent ICC) underwent curative IORFA with hepatic resection for surgically unresectable ICC. Patients were not qualified to undergo surgical resection due to multiple lesions causing postoperative hepatic insufficiency and undesirable tumor locations for surgical resection or percutaneous RFA. Of the 51 treated tumors (mean, 2.6±0.9 tumors/patient), 24 were treated by IORFA and 27 were surgically removed. The technical success and effectiveness, overall survival, progression-free survival (PFS), and complications were assessed retrospectively. The overall survival and PFS rates were estimated by the Kaplan-Meier method. RESULTS The technical success and effectiveness of IORFA were 100%. The overall survival rates at 6 months, 1, 3, and 5 years were 95%, 79%, 27%, and 14%, respectively. The median overall survival time was 22.0±3.45 months. The PFS rates at 6 months, 1, 3, and 5 years were 70%, 33%, 13%, and 13%, respectively. The median PFS was 9.0±1.68 months. The prognosis was significantly worse for patients with recurrent ICC than for patients with primary ICC. One patient (5%) had major complications due to IORFA such as liver abscess and biliary stricture. CONCLUSION IORFA with surgical resection can be a feasible option for ICC cases that are not amenable to treatment with surgical resection alone. This strategy provides acceptable local tumor control and overall survival.

Entities:  

Mesh:

Year:  2020        PMID: 31904570      PMCID: PMC7075581          DOI: 10.5152/dir.2019.18552

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  39 in total

1.  Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival.

Authors:  Giorgio Ercolani; Gaetano Vetrone; Gian Luca Grazi; Osamu Aramaki; Matteo Cescon; Matteo Ravaioli; Carla Serra; Giovanni Brandi; Antonio Daniele Pinna
Journal:  Ann Surg       Date:  2010-07       Impact factor: 12.969

2.  Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system.

Authors:  Steven M Strasberg
Journal:  J Hepatobiliary Pancreat Surg       Date:  2005

Review 3.  Cholangiocarcinoma: pictorial essay of CT and cholangiographic findings.

Authors:  Joon Koo Han; Byung Ihn Choi; Ah Young Kim; Su Kyung An; Joon Woo Lee; Tae Kyung Kim; Sun-Whe Kim
Journal:  Radiographics       Date:  2002 Jan-Feb       Impact factor: 5.333

4.  Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma.

Authors:  Jin Hyoung Kim; Hyung Jin Won; Yong Moon Shin; Kyung-Ah Kim; Pyo Nyun Kim
Journal:  AJR Am J Roentgenol       Date:  2011-02       Impact factor: 3.959

Review 5.  Chemotherapy for advanced cholangiocarcinoma: what is standard treatment?

Authors:  Danish Mazhar; Justin Stebbing; Mark Bower
Journal:  Future Oncol       Date:  2006-08       Impact factor: 3.404

6.  Hepatic resection and transplantation for peripheral cholangiocarcinoma.

Authors:  F A Casavilla; J W Marsh; S Iwatsuki; S Todo; R G Lee; J R Madariaga; A Pinna; I Dvorchik; J J Fung; T E Starzl
Journal:  J Am Coll Surg       Date:  1997-11       Impact factor: 6.113

7.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

8.  Intraoperative radiofrequency ablation (RFA) for irresectable liver malignancies.

Authors:  J Tepel; S Hinz; H-J Klomp; M Kapischke; B Kremer
Journal:  Eur J Surg Oncol       Date:  2004-06       Impact factor: 4.424

9.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

10.  Intraoperative ablation for small HCC not amenable for percutaneous radiofrequency ablation in Child A cirrhotic patients.

Authors:  Ahmed El-Gendi; Mohamed El-Shafei; Fatma Abdel-Aziz; Essam Bedewy
Journal:  J Gastrointest Surg       Date:  2012-11-21       Impact factor: 3.452

View more
  2 in total

1.  Surgical Resection plus Intraoperative Radiofrequency Ablation versus Chemoembolization for the Treatment of Intermediate-Stage (BCLC B) Hepatocellular Carcinoma with Preserved Liver Function: A Propensity Score-Matched Analysis.

Authors:  Gun Ha Kim; Jin Hyoung Kim; Heung Kyu Ko; Hee Ho Chu; Seong Ho Kim; Ji Hoon Shin; Dong Il Gwon; Gi-Young Ko; Hyun-Ki Yoon; Ki-Hun Kim; Ju Hyun Shim; Nayoung Kim
Journal:  Cancers (Basel)       Date:  2022-05-15       Impact factor: 6.575

Review 2.  Diagnostic and procedural intraoperative ultrasound: technique, tips and tricks for optimizing results.

Authors:  Meghan G Lubner; Lori Mankowski Gettle; David H Kim; Timothy J Ziemlewicz; Nirvikar Dahiya; Perry Pickhardt
Journal:  Br J Radiol       Date:  2021-03-08       Impact factor: 3.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.